SELLAS Receives EMA Orphan Drug Designation For SLS009 For Treatment Of Peripheral T-Cell Lymphomas
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) has received Orphan Drug Designation from the European Medicines Agency for its novel CDK9 inhibitor, SLS009, aimed at treating relapsed/refractory peripheral T-cell lymphomas.

August 06, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences Group, Inc. has been granted Orphan Drug Designation by the EMA for its CDK9 inhibitor, SLS009, for treating relapsed/refractory peripheral T-cell lymphomas. This designation could expedite the drug's development and approval process, potentially leading to increased investor interest and a positive short-term impact on the stock price.
The Orphan Drug Designation by the EMA is a significant regulatory milestone that can accelerate the development and approval process of SLS009. This news is likely to attract investor interest and boost the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100